Vitamin D and vascular calcification in chronic kidney disease

Bone

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Mizobuchi, Masahide ^a   Ogata, Hiroaki ^b   Koiwa, Fumihiko ^c   Kinugasa, Eriko ^b   Akizawa, Tadao ^a  

^a SHOWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

Author keywords

Calcium; Cardiovascular disease; Chronic kidney disease; Phosphate; Vascular calcification; Vitamin D

Indexed keywords

BINDING PROTEIN; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS; PROTEIN CORE BINDING FACTOR 1; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; HEART MUSCLE CELL; HORMONE BLOOD LEVEL; HUMAN; NEPHRECTOMY; NONHUMAN; OSTEOBLAST; PHOSPHATE BLOOD LEVEL; SMOOTH MUSCLE FIBER; UREMIA; VITAMIN D DEFICIENCY;

ANIMALS; CALCINOSIS; HUMANS; KIDNEY FAILURE, CHRONIC; OSTEOGENESIS; VASCULAR DISEASES; VITAMIN D;

EID: 67349216176     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.01.011     Document Type: Article

References (61)

1. Goodman W.G., London G., Amann K., et al. Vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 43 (2004) 572-579
2. Shroff R.C., and Shanahan C.M. The vascular biology of calcification. Semin. Dial 20 (2007) 103-109
3. Somjen D., Weisman Y., Kohen F., et al. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 111 (2005) 1666-1671
4. 2+-uptake by cultured vascular smooth muscle cells derived from rat aorta. Biochem. Biophys. Res. Commun. 152 (1988) 1388-1394
5. Rajasree S., Umashankar P.R., Lal A.V., Sarma P.S., and Kartha C.C. 1,25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci. 70 (2002) 1777-1788
6. Wu-Wong J.R., Nakane M., Ma J., Ruan X., and Kroeger P.E. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. Atherosclerosis 186 (2006) 20-28
7. Wu-Wong J.R., Nakane M., Ma J., Ruan X., and Kroeger P.E. VDR-mediated gene expression patterns in resting human coronary artery smooth muscle cells. J. Cell Biochem. 100 (2007) 1395-1405
8. Dusso A.S., Brown A.J., and Slatopolsky E. Vitamin D. Am. J. Physiol. Renal. Physiol. 289 (2005) F8-F28
9. Brown A.J., and Slatopolsky E. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol. Aspects Med. (2008)
10. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42 (2003) S1-S201
11. Matias P.J., Ferreira C., Jorge C., et al. 25-Hydroxyvitamin D3, arterial calcifications and cardiovascular risk markers in haemodialysis patients. Nephrol. Dial Transplant (2008)
12. Derici U., and El Nahas A.M. Vascular calcifications in uremia: old concepts and new insights. Semin. Dial 19 (2006) 60-68
13. Johnson R.C., Leopold J.A., and Loscalzo J. Vascular calcification: pathobiological mechanisms and clinical implications. Circ. Res. 99 (2006) 1044-1059
14. Shroff R., Egerton M., Bridel M., et al. A bimodal association of vitamin D levels and vascular disease in children on dialysis. J. Am. Soc. Nephrol. 19 (2008) 1239-1246
15. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 70 (2006) 771-780
16. Tentori F., Hunt W.C., Stidley C.A., et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 70 (2006) 1858-1865
17. Shoji T., Shinohara K., Kimoto E., et al. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial Transplant 19 (2004) 179-184
18. Teng M., Wolf M., Ofsthun M.N., et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 16 (2005) 1115-1125
19. Teng M., Wolf M., Lowrie E., Ofsthun N., Lazarus J.M., and Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 349 (2003) 446-456
20. Kovesdy C.P., Ahmadzadeh S., Anderson J.E., and Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch. Intern. Med. 168 (2008) 397-403
21. Shoben A.B., Rudser K.D., de Boer I.H., Young B., and Kestenbaum B. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 19 (2008) 1613-1619
22. Giachelli C.M., Speer M.Y., Li X., Rajachar R.M., and Yang H. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ. Res. 96 (2005) 717-722
23. Moe S.M., and Chen N.X. Mechanisms of vascular calcification in chronic kidney disease. J. Am. Soc. Nephrol. 19 (2008) 213-216
24. Shanahan C.M. Vascular calcification. Curr. Opin. Nephrol. Hypertens. 14 (2005) 361-367
25. Moe S.M., Reslerova M., Ketteler M., et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 67 (2005) 2295-2304
26. Jono S., McKee M.D., Murry C.E., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87 (2000) E10-E17
27. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., and Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 63 (2003) 1003-1011
28. Mizobuchi M., Ogata H., Hatamura I., et al. Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. Nephrol. Dial Transplant 21 (2006) 911-916
29. Ketteler M. Fetuin-A and extraosseous calcification in uremia. Curr. Opin. Nephrol. Hypertens. 14 (2005) 337-342
30. Bostrom K. Insights into the mechanism of vascular calcification. Am. J. Cardiol. 88 (2001) 20E-22E
31. Shroff R.C., Shah V., Hiorns M.P., et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol. Dial Transplant (2008)
32. Cranenburg E.C., Vermeer C., Koos R., et al. The circulating inactive form of matrix Gla protein (ucMGP) as a biomarker for cardiovascular calcification. J. Vasc. Res. 45 (2008) 427-436
33. Carthy E.P., Yamashita W., Hsu A., and Ooi B.S. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Hypertension 13 (1989) 954-959
34. Cardus A., Gallego C., Muray S., et al. [Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells]. Nefrologia. 23 Suppl 2 (2003) 117-121
35. Jono S., Nishizawa Y., Shioi A., and Morii H. 1,25-Dihydroxyvitamin D3 increases in vitro vascular calcification by modulating secretion of endogenous parathyroid hormone-related peptide. Circulation 98 (1998) 1302-1306
36. Cardus A., Panizo S., Parisi E., Fernandez E., and Valdivielso J.M. Differential effects of vitamin D analogs on vascular calcification. J. Bone Miner. Res. 22 (2007) 860-866
37. Wu-Wong J.R., Noonan W., Ma J., et al. Role of phosphorus and vitamin D analogs in the pathogenesis of vascular calcification. J. Pharmacol. Exp. Ther. 318 (2006) 90-98
38. Wolisi G.O., and Moe S.M. The role of vitamin D in vascular calcification in chronic kidney disease. Semin. Dial 18 (2005) 307-314
39. Cardus A., Parisi E., Gallego C., Aldea M., Fernandez E., and Valdivielso J.M. 1,25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int. 69 (2006) 1377-1384
40. Haffner D., Hocher B., Muller D., et al. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J. Hypertens. 23 (2005) 1067-1075
41. Henley C., Colloton M., Cattley R.C., et al. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Nephrol. Dial Transplant 20 (2005) 1370-1377
42. Hirata M., Katsumata K., Endo K., Fukushima N., Ohkawa H., and Fukagawa M. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol. Dial Transplant 18 (2003) 1770-1776
43. Lopez I., Aguilera-Tejero E., Mendoza F.J., et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. 17 (2006) 795-804
44. Tamura K., Suzuki Y., Hashiba H., Tamura H., Aizawa S., and Kogo H. Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy. J. Pharmacol. Sci. 99 (2005) 89-94
45. Tamura K., Suzuki Y., Matsushita M., et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur. J. Pharmacol. 558 (2007) 159-166
46. Verberckmoes S.C., Persy V., Behets G.J., et al. Uremia-related vascular calcification: more than apatite deposition. Kidney Int. 71 (2007) 298-303
47. Mizobuchi M., Finch J.L., Martin D.R., and Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 72 (2007) 709-715
48. Noonan W., Koch K., Nakane M., et al. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol. Dial Transplant (2008)
49. Watson K.E., Abrolat M.L., Malone L.L., et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 96 (1997) 1755-1760
50. Doherty T.M., Tang W., Dascalos S., et al. Ethnic origin and serum levels of 1alpha,25-dihydroxyvitamin D3 are independent predictors of coronary calcium mass measured by electron-beam computed tomography. Circulation 96 (1997) 1477-1481
51. Goldsmith D.J., Covic A., Sambrook P.A., and Ackrill P. Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis. Nephron 77 (1997) 37-43
52. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., and de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J. Am. Soc. Nephrol. 15 (2004) 1943-1951
53. Goodman W.G., Ramirez J.A., Belin T.R., et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 46 (1994) 1160-1166
54. Raggi P., Boulay A., Chasan-Taber S., et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease?. J. Am. Coll. Cardiol. 39 (2002) 695-701
55. Craver L., Marco M.P., Martinez I., Rue M., Borras M., Martin M.L., Sarro F., Valdivielso J.M., and Fernandez E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol. Dial Transplant 22 (2007) 1171-1176
56. Levin A., Bakris G.L., Molitch M., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 71 (2007) 31-38
57. Nibbelink K.A., Tishkoff D.X., Hershey S.D., Rahman A., and Simpson R.U. 1,25(OH)2-vitamin D3 actions on cell proliferation, size, gene expression, and receptor localization, in the HL-1 cardiac myocyte. J. Steroid Biochem. Mol. Biol. 103 (2007) 533-537
58. Tishkoff D.X., Nibbelink K.A., Holmberg K.H., Dandu L., and Simpson R.U. Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149 (2008) 558-564
59. McGonigle R.J., Fowler M.B., Timmis A.B., Weston M.J., and Parsons V. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron. 36 (1984) 94-100
60. Park C.W., Oh Y.S., Shin Y.S., et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am. J. Kidney Dis. 33 (1999) 73-81
61. Xiang W., Kong J., Chen S., et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am. J. Physiol. Endocrinol. Metab. 288 (2005) E125-E132